Clinical Trial Failure or Delay: Cellectar's success hinges on the successful completion of its ongoing and future clinical trials, particularly the pivotal study for iopofosine. Failure to achieve primary or secondary endpoints, unexpected adverse events, or significant delays in trial enrollment or data analysis could severely impact its prospects and stock value.

Failure to Obtain Regulatory Approval: Even with positive clinical data, there is no guarantee that regulatory authorities like the FDA or EMA will grant marketing approval for its drug candidates. Regulatory bodies may require additional studies, raise concerns about safety or efficacy, or otherwise delay or deny approval, preventing the company from commercializing its products.

Need for Additional Capital: Cellectar is a clinical-stage company with no commercial products generating significant revenue. It relies heavily on external financing to fund its expensive research, development, and clinical trial activities. Failure to secure additional capital on favorable terms when needed could force the company to delay, reduce, or terminate its development programs.